Analysis of marketed orphan drugs in China-Reference-Cited by-同舟云学术

Analysis of marketed orphan drugs in China

Published:2023-08-31 Issue:3 Volume:12 Page:132-140
ISSN:2186-361X
Container-title:Intractable & Rare Diseases Research
language:en
Short-container-title:IRDR

Author:

Zhi Wei¹,Liu Meilin¹,Yang Dan¹,Zhang Shanshan¹,Lu Yanqin¹,Han Jinxiang¹

Affiliation:

1. Key Laboratory for Biotech Drugs of the National Health Commission, Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Ji'nan, Shandong, China.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/irdr/12/3/12_2023.01030/_pdf

Reference15 articles.

1. 1. Lu J, Pan X. Current situation and future of rare diseases in China. China Tropical Medicine. 2023; 23:109-114. (in Chinese)

2. 2. Chung CCY; Hong Kong Genome Project; Chu ATW, Chung BHY. Rare disease emerging as a global public health priority. Front Public Health. 2022; 10:1028545.

3. 3. Gopal-Srivastava R, Kaufmann P. Facilitating clinical studies in rare diseases. Adv Exp Med Biol. 2017; 1031:125-140.

4. 4. FDA Newsroom. Taking New Steps to Meet the Challenges of Rare Diseases — FDA Marks the 11th Rare Disease Day. https://www.fda.gov/news-events/fda-voices/taking-new-steps-meet-challenges-rare-diseases-fda-marks-11th-rare-disease-day (accessed March 14, 2023).

5. 5. European Medicines Agency. Market exclusivity: orphan medicines. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/orphan-medicines/market-exclusivity-orphan-medicines (accessed March 14, 2023).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Orphan drug policy analysis in China;Frontiers in Pharmacology;2024-06-13